< Back to latest news & events

Knowledge Hub

A new dawn for European patents and patent litigation – 1 June 2023

June 2023

Just as the UPC’s sunrise phase has ended, a new dawn is breaking for European patents and patent litigation.  After many years of anticipation, the Unified Patent Court (UPC) and a new “European patent with unitary effect” or “unitary patent” (UP) are now a reality.

 

The primary aim of the UPC is to provide a harmonised system of patent litigation, within a single set of proceedings, within the participating EU member states.  At present there are 17 EU MS who have ratified the UPC Agreement and will participate in the UP.  This is expected to rise to at least 18 EU MS in 2024 if Ireland’s UPC referendum is approved and could rise to 24 EU MS, or even to all EU MS should Spain, Poland and Croatia decide to sign up to the UPC Agreement.

 

From today, the UPC has exclusive jurisdiction over all European patents that have not been opted-out of its jurisdiction.  Patentees will be able to enforce their EP bundle or UP in a single action before the UPC and third-party challengers will be able to bring claims and counterclaims for revocation.  The UPC can also order provisional measures, including preliminary injunctions and seizure of evidence of infringement (saisie).  During a 7 year transitional phase, where EPs have not been opted-out both the UPC and the national patent courts can hear matters, which allows for a degree of forum shopping between the courts, as well as a possible resurgence of torpedo litigations.

 

Our expectation is that the first UPs will be granted on 7 June 2023 and create a unitary patent right across all 17 EU MS that have ratified the UPC Agreement currently (including Germany, France, Italy and The Netherlands).  These UPs will benefit from a single renewal fee, payable to the EPO that has been set to approximately the costs of validating an EP in 4 EU MS, which for some patentees will represent a significant saving.  The renewal fee must be paid in full each year and cannot be reduced by “dropping” coverage of certain UPC countries.  As with all EPs, the UP can be opposed as part of the EPO’s central opposition procedures (alongside any other EP nationals) within 9 months of grant.  The UP can only be enforced or centrally revoked in litigation before the UPC.

 

During the three-months leading up to the launch of the UPC, approximately 460,000 European patents and patent applications have been opted-out.  Provided no litigation has been launched before the UPC, applications to opt-out can be filed for at least the next 7 years.  We expect that many patentees will continue to file applications to opt-out before grant of the EP while watching how the UPC develops.  The opt-out will last for the lifetime of the EP unless it is withdrawn.  An application to withdraw the opt-out can be filed at any time during the lifetime of the EP unless there has been any national litigation (pending or concluded).

 

With a team of specialist European patent litigators, oppositions specialists and patent attorney teams who bring together an extensive depth of legal and technical knowledge, HGF is ideally placed to advise on the impact of the UPC on patent litigation, prosecution and licensing strategy.  For further information please contact upclitigation@hgf.com or speak to your usual HGF attorney.

 

 

Latest updates

The Antibody Series #5 | Epitope-defined antibody claims: when “binds to this epitope” becomes a risk of insufficiency

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews decisions made at the EPO; here, they reviewed an appeal in opposition proceedings after the revocation …

Read article

The Deity Shoes case: a question of design activity and the constraints on a designer’s freedom

The footwear brand Deity Shoes sought to enforce their Community Design rights, both registered and unregistered, against Mundorama Confort and Stay Design. However, Mundorama Confort and Stay Design found fault …

Read article

The Antibody Series #4 | pH points in antibody claims: when “same pH ” becomes an addition of matter

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions; in this case, they reviewed a revocation in opposition of a patent relating to …

Read article

The Antibody Series #3 | Antibody code names in claims: why “ACZ885” is not sufficient to define the antibody

The Boards of Appeal of the EPO (BoA) are the appeal body that reviews EPO decisions. In this case, they examined a claim that identified an antibody by an internal …

Read article
Event - 3rd February 2026

HGF Brand & Design Conference 2026

Join us on 3rd February 2026 for HGF’s Brand & Design Conference, the must attend event for in-house legal teams, brand leaders, creatives, and innovators shaping the future of IP. …

Event details

Office Closed Dates December 2025 / January 2026

HGF Office Closed Dates December 2025 / January 2026   UK Thursday 25 and Friday 26 December 2025 CLOSED Thursday 1 January 2026* CLOSED * Friday 2 January 2026 – …

Read article
Event - 14th January 2026

Seminar on The aftermath of G1/24 - has anything changed?

HGF is hosting a The aftermath of G1/24 – has anything changed? Which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 14th January …

Event details

Zombie Fashion Brands

Episode 4 Zombie Fashion Brands  

Read article